Volume sensitivity of blood pressure in end-stage renal disease. 1997

J E Ventura, and M Spósito
Centro de Nefrología de la Universidad de la República, Montevideo, Uruguay.

BACKGROUND The influence of interdialysis (ID) volume expansion on the blood pressure (BP) change and on the BP level at the end of the ID time period was studied in 167 chronic haemodialysis patients. Our analysis focused on 120 patients not receiving antihypertensive drugs (untreated group). The remaining 47 patients were receiving antihypertensive medication (treated group). METHODS The ID weight gain was considered equivalent to the volume gain. In each patient the mean ID BP change (as percent change of initial BP) and the mean ID volume expansion related to the lean body mass (ml.kg-1) were determined from 25 consecutive ID time periods. The individual volume sensitivity of BP was expressed as the BP change divided by the volume expansion. Basal overhydration was estimated as mean ID initial weight minus dry weight. RESULTS All patients gained volume during ID time periods and the BP was increased in 91%. The change of mean BP (MBP) was directly correlated with volume expansion (r = 0.45, P < 0.00001) only in the untreated group. These patients showed a volume sensitivity unrelated with age, serum urea and calcium concentrations and haematocrit. Sensitivity of diastolic BP (DBP), an indicator of the capacity to respond to volume expansion by vasoconstriction (autoregulatory process), exhibited a negative correlation with the initial DBP level (r = -0.36, P < 0.0001) and with the serum potassium (in women, r = -0.35, p < 0.02). These factors appeared to counteract the volume-induced DBP response. The MBP levels at the end of ID time periods were independent of volume expansion and basal overhydration. Hypertensive patients showed a higher sensitivity than normotensive patients (0.35 +/- 0.2 versus 0.20 +/- 0.19% per ml.kg-1, P < 0.005). Final MBP showed a positive correlation with initial MBP and, to a smaller extent, with serum urea concentration. CONCLUSIONS In our study the ID change of BP is partially dependent on volume gain. Volume sensitivity is a measure of the BP responsiveness and is higher in hypertensive patients. Final BP depends on the height of initial BP and other factors accounting for volume sensitivity, whose precise nature remain to be clarified.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010953 Plasma Volume Volume of PLASMA in the circulation. It is usually measured by INDICATOR DILUTION TECHNIQUES. Blood Plasma Volume,Blood Plasma Volumes,Plasma Volumes,Volume, Blood Plasma,Volume, Plasma,Volumes, Blood Plasma,Volumes, Plasma
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D005260 Female Females
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000959 Antihypertensive Agents Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive
D014511 Uremia A clinical syndrome associated with the retention of renal waste products or uremic toxins in the blood. It is usually the result of RENAL INSUFFICIENCY. Most uremic toxins are end products of protein or nitrogen CATABOLISM, such as UREA or CREATININE. Severe uremia can lead to multiple organ dysfunctions with a constellation of symptoms. Uremias

Related Publications

J E Ventura, and M Spósito
December 1997, Blood pressure monitoring,
J E Ventura, and M Spósito
January 1996, The New England journal of medicine,
J E Ventura, and M Spósito
June 1975, Circulation research,
J E Ventura, and M Spósito
June 1988, Lancet (London, England),
J E Ventura, and M Spósito
January 2010, Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference,
J E Ventura, and M Spósito
January 2012, The Journal of clinical investigation,
J E Ventura, and M Spósito
August 1996, American journal of hypertension,
J E Ventura, and M Spósito
June 2000, Clinical pharmacokinetics,
J E Ventura, and M Spósito
April 1997, Evidence-based cardiovascular medicine,
J E Ventura, and M Spósito
December 1998, Journal of the American Society of Nephrology : JASN,
Copied contents to your clipboard!